MGLL and status epilepticus: Mice in the study by Terrone et al. [32] were treated with the irreversible MAGL inhibitor CPD-4645 after status epilepticus onset (KA treatment), whereas mice were treated with the MAGL inhibitor compound 4f prior to KA treatment in our study.